期刊文献+

热疗对荷VX_2瘤动物细胞因子影响的实验研究 被引量:24

Effect of hyperthermia on VX_2 carcinoma bearing rabbits
原文传递
导出
摘要 目的探讨热疗对荷VX2瘤动物细胞因子的影响。方法选健康雄性大白兔40只,随机分为热疗组20只、对照组20只。移植VX2瘤株11d后,对实验组动物进行热疗照射,监测白介素-2(IL-2)、肿瘤坏死因子(TNF)、胰岛素样生长因子(IGF)的变化。结果实验动物生存期较对照组延长15d左右。移植前IL-2、TNF、IGF为(134±6)ng/ml、(4·5±0·9)ng/ml、(96±28)ng/ml;治疗后1周为(81±7)ng/ml、(7·6±1·8)ng/ml、(678±183)ng/ml;3周为(61·8±2·0)ng/ml、(15·1±3·0)ng/ml、(991±108)ng/ml;4周为(54·8±2·6)ng/ml、(17·2±2·1)ng/ml、(1136±89)ng/ml。结论热疗对于表浅肿瘤的治疗是有效的辅助疗法;热疗后肿瘤细胞变性坏死的分解产物被机体吸收后作为一种抗原,刺激机体的免疫系统产生细胞因子,起到抗肿瘤免疫功能。 Objective To study the effect of hyperthermia on cytokines of VX2 carcinoma bearing rabbits. Method Forty healthy male rabbits were randomly divided into heat therapy group and control group. Rabbits in heat therapy group underwent hyperthermia 11 days after inoculated with VX2 cells. IL-2, tumor necrosis factor (TNF) and insulinlike growth factor (IGF) were measured before and after heat therapy. Results In heat therapy group survival was prolonged for 15 days. IL-2 decreased gradually from ( 134 ± 6) ng/ml before heat therapy, ( 81±7 ) ng/ml one week after, (61.8 v 2. 0) ng/ml at 3 weeks, and (54. 8±2.6) ng/ml at 4 weeks along with an increase of TNF and IGF (4. 5±0. 9) ng/ml, and (96 ±28) ng/ml; (7.6± 1.8) ng/ml and (678±183) ng,/ml; (15.1±3.0) ng,/ml and (991 ±108) ng/ml; ( 17. 2 ± 2. 1 ) ng/ml and ( 1136 ± 89 ) ng/ml respectively at the corresponding time period. Conclusion Heat therapy is effective for the treatment of superficial tumors probably through a mechanism of antigenantibody reaction.
出处 《中华普通外科杂志》 CSCD 北大核心 2005年第9期591-593,共3页 Chinese Journal of General Surgery
关键词 热疗 荷VX2瘤动物 细胞因子 动物实验 肿瘤细胞 表浅肿瘤 免疫功能 Neoplasms Diathermy Tumor necrosis factor Interleukin
  • 相关文献

参考文献4

二级参考文献13

  • 1胡永成.肿瘤局部热疗与免疫[J].国外医学(肿瘤学分册),1994,21(4):216-216. 被引量:33
  • 2曾蒙苏,张宏伟,周康荣,陆宏祺,严惠芳.供影像学诊断实验的大鼠移植肝癌模型的可行性研究[J].临床放射学杂志,1996,15(1):56-59. 被引量:14
  • 3Conomus JS,Hoban M,Lee JD,et al. Production of tumor necrosis factor alpha and interferon gamma in interleukine-2 treated melanoma patients:correlation with clinical toxicity[J].Cancer Immunol Immunother,1991,34:49-52.
  • 4Oldham RK.Biologicals and biological response modifiers:fourth modality of cancer treatment[J]. Cancer Treat Rep. 1984 Jan;68(1):221-32.
  • 51 Alan F,Holmer.The century of biology begins with 369 biotechnology medicines in testing for more than 200 diseases[M].New medicine in development biotechnology,2000:1.
  • 6Frucht DM. IL-23:a cytokine that acts on memory T cells[J].Sci STKE. 2002 Jan 8;2002(114):PE1. Review.
  • 7Fujita T, Tamura T, Yamada H, et al. Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice[J].J Drug Target. 1997;4(5):289-96.
  • 8Alan F.Holmer.The century of biology begins with 369 biotechnology medicines in testing for more than 200 disease[M]. New medicine in development Biotechnology,2000:1-5.
  • 9Ettinghausen SE,Moore JG,White DE,et al.Hematalogic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukine-2 in cancer patients[J].Blood,1987,69(6):1654-1660.
  • 10Lee RE,Lotze HM,Skibber JM,et al. Cardiorespiratory effects of immunotherapy with interleukine-2[J]. J Clin Oncol,1989,7(1):7-20.

共引文献94

同被引文献135

引证文献24

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部